Selected research
Market Structure
Global Next-Generation Tumor Genetic Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Next-Generation Tumor Genetic Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Next-Generation Tumor Genetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Next-Generation Tumor Genetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Next-Generation Tumor Genetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Next-Generation Tumor Genetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Next-Generation Tumor Genetic Testing include Devyser, Agendia, Illumina, Personal Genome Diagnostics, Veracyte, Pacific Biosciences of California, Qiagen, Agilent Technologies and Natera, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Next-Generation Tumor Genetic Testing market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Next-Generation Tumor Genetic Testing and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Next-Generation Tumor Genetic Testing revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Next-Generation Tumor Genetic Testing market size, projected growth trends, production technologies, key applications, and end-use industries.
Next-Generation Tumor Genetic Testing Segment by Company
Devyser
Agendia
Illumina
Personal Genome Diagnostics
Veracyte
Pacific Biosciences of California
Qiagen
Agilent Technologies
Natera
Bio Rad Laboratories
Myriad Genetics
Next-Generation Tumor Genetic Testing Segment by Type
Fluorescence In Situ Hybridization
Polymerase Chain Reaction
Microarray Technology
Serum Proteomics
Nucleic Acid Sequencing
Next-Generation Tumor Genetic Testing Segment by Application
Hospitals
Speciality Clinics
Research Institutes
Diagnostics Laboratories
Biopharmaceutical Companies
Next-Generation Tumor Genetic Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Next-Generation Tumor Genetic Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Next-Generation Tumor Genetic Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Next-Generation Tumor Genetic Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Next-Generation Tumor Genetic Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Next-Generation Tumor Genetic Testing industry.
Chapter 3: Detailed analysis of Next-Generation Tumor Genetic Testing companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Next-Generation Tumor Genetic Testingrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fluorescence In Situ Hybridization
- Polymerase Chain Reaction
- Microarray Technology
- Serum Proteomics
- Nucleic Acid Sequencing
Applications
- Hospitals
- Speciality Clinics
- Research Institutes
- Diagnostics Laboratories
- Biopharmaceutical Companies
Companies covered
- Devyser
- Agendia
- Illumina
- Personal Genome Diagnostics
- Veracyte
- Pacific Biosciences of California
- Qiagen
- Agilent Technologies
- Natera
- Bio Rad Laboratories
- Myriad Genetics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Next-Generation Tumor Genetic Testing Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Fluorescence In Situ Hybridization
- 1.2.3 Polymerase Chain Reaction
- 1.2.4 Microarray Technology
- 1.2.5 Serum Proteomics
- 1.2.6 Nucleic Acid Sequencing
- 1.3 Market Analysis by Application
- 1.3.1 Global Next-Generation Tumor Genetic Testing Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospitals
- 1.3.3 Speciality Clinics
- 1.3.4 Research Institutes
- 1.3.5 Diagnostics Laboratories
- 1.3.6 Biopharmaceutical Companies
- 1.4 Global Market Growth Prospects
- 1.5 Global Next-Generation Tumor Genetic Testing Growth Trends by Region
- 1.5.1 Global Next-Generation Tumor Genetic Testing Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Next-Generation Tumor Genetic Testing Market Size by Region (2021-2026)
- 1.5.3 Next-Generation Tumor Genetic Testing Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Next-Generation Tumor Genetic Testing Market Dynamics
- 2.1 Next-Generation Tumor Genetic Testing Industry Trends
- 2.2 Next-Generation Tumor Genetic Testing Industry Drivers
- 2.3 Next-Generation Tumor Genetic Testing Industry Opportunities and Challenges
- 2.4 Next-Generation Tumor Genetic Testing Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Next-Generation Tumor Genetic Testing Revenue by Company (2021-2026)
- 3.2 Global Next-Generation Tumor Genetic Testing Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Next-Generation Tumor Genetic Testing Key Company Head office and Area Served
- 3.4 Global Next-Generation Tumor Genetic Testing Company, Product Type & Application
- 3.5 Global Next-Generation Tumor Genetic Testing Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Next-Generation Tumor Genetic Testing Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Next-Generation Tumor Genetic Testing Players Market Share by Revenue in 2025
- 3.6.3 2025 Next-Generation Tumor Genetic Testing Tier 1, Tier 2, and Tier 3
4 Next-Generation Tumor Genetic Testing Market by Type
- 4.1 Global Next-Generation Tumor Genetic Testing Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Next-Generation Tumor Genetic Testing Market Size by Type (2021-2032)
- 4.3 Global Next-Generation Tumor Genetic Testing Market Size Share by Type (2021-2032)
5 Next-Generation Tumor Genetic Testing Market by Application
- 5.1 Global Next-Generation Tumor Genetic Testing Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Next-Generation Tumor Genetic Testing Market Size by Application (2021-2032)
- 5.3 Global Next-Generation Tumor Genetic Testing Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Devyser
- 6.1.1 Devyser Company Information
- 6.1.2 Devyser Business Overview
- 6.1.3 Devyser Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Devyser Next-Generation Tumor Genetic Testing Product Portfolio
- 6.1.5 Devyser Recent Developments
- 6.2 Agendia
- 6.2.1 Agendia Company Information
- 6.2.2 Agendia Business Overview
- 6.2.3 Agendia Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Agendia Next-Generation Tumor Genetic Testing Product Portfolio
- 6.2.5 Agendia Recent Developments
- 6.3 Illumina
- 6.3.1 Illumina Company Information
- 6.3.2 Illumina Business Overview
- 6.3.3 Illumina Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Illumina Next-Generation Tumor Genetic Testing Product Portfolio
- 6.3.5 Illumina Recent Developments
- 6.4 Personal Genome Diagnostics
- 6.4.1 Personal Genome Diagnostics Company Information
- 6.4.2 Personal Genome Diagnostics Business Overview
- 6.4.3 Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Product Portfolio
- 6.4.5 Personal Genome Diagnostics Recent Developments
- 6.5 Veracyte
- 6.5.1 Veracyte Company Information
- 6.5.2 Veracyte Business Overview
- 6.5.3 Veracyte Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Veracyte Next-Generation Tumor Genetic Testing Product Portfolio
- 6.5.5 Veracyte Recent Developments
- 6.6 Pacific Biosciences of California
- 6.6.1 Pacific Biosciences of California Company Information
- 6.6.2 Pacific Biosciences of California Business Overview
- 6.6.3 Pacific Biosciences of California Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Pacific Biosciences of California Next-Generation Tumor Genetic Testing Product Portfolio
- 6.6.5 Pacific Biosciences of California Recent Developments
- 6.7 Qiagen
- 6.7.1 Qiagen Company Information
- 6.7.2 Qiagen Business Overview
- 6.7.3 Qiagen Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Qiagen Next-Generation Tumor Genetic Testing Product Portfolio
- 6.7.5 Qiagen Recent Developments
- 6.8 Agilent Technologies
- 6.8.1 Agilent Technologies Company Information
- 6.8.2 Agilent Technologies Business Overview
- 6.8.3 Agilent Technologies Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Agilent Technologies Next-Generation Tumor Genetic Testing Product Portfolio
- 6.8.5 Agilent Technologies Recent Developments
- 6.9 Natera
- 6.9.1 Natera Company Information
- 6.9.2 Natera Business Overview
- 6.9.3 Natera Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Natera Next-Generation Tumor Genetic Testing Product Portfolio
- 6.9.5 Natera Recent Developments
- 6.10 Bio Rad Laboratories
- 6.10.1 Bio Rad Laboratories Company Information
- 6.10.2 Bio Rad Laboratories Business Overview
- 6.10.3 Bio Rad Laboratories Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Bio Rad Laboratories Next-Generation Tumor Genetic Testing Product Portfolio
- 6.10.5 Bio Rad Laboratories Recent Developments
- 6.11 Myriad Genetics
- 6.11.1 Myriad Genetics Company Information
- 6.11.2 Myriad Genetics Business Overview
- 6.11.3 Myriad Genetics Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Myriad Genetics Next-Generation Tumor Genetic Testing Product Portfolio
- 6.11.5 Myriad Genetics Recent Developments
7 North America
- 7.1 North America Next-Generation Tumor Genetic Testing Market Size (2021-2032)
- 7.2 North America Next-Generation Tumor Genetic Testing Market Size by Type
- 7.2.1 North America Next-Generation Tumor Genetic Testing Market Size by Type (2021-2026)
- 7.2.2 North America Next-Generation Tumor Genetic Testing Market Size by Type (2027-2032)
- 7.2.3 North America Next-Generation Tumor Genetic Testing Market Share by Type (2021-2032)
- 7.3 North America Next-Generation Tumor Genetic Testing Market Size by Application
- 7.3.1 North America Next-Generation Tumor Genetic Testing Market Size by Application (2021-2026)
- 7.3.2 North America Next-Generation Tumor Genetic Testing Market Size by Application (2027-2032)
- 7.3.3 North America Next-Generation Tumor Genetic Testing Market Share by Application (2021-2032)
- 7.4 North America Next-Generation Tumor Genetic Testing Market Size by Country
- 7.4.1 North America Next-Generation Tumor Genetic Testing Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 7.4.3 North America Next-Generation Tumor Genetic Testing Market Size by Country (2027-2032)
- 7.4.4 North America Next-Generation Tumor Genetic Testing Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Next-Generation Tumor Genetic Testing Market Size (2021-2032)
- 8.2 Europe Next-Generation Tumor Genetic Testing Market Size by Type
- 8.2.1 Europe Next-Generation Tumor Genetic Testing Market Size by Type (2021-2026)
- 8.2.2 Europe Next-Generation Tumor Genetic Testing Market Size by Type (2027-2032)
- 8.2.3 Europe Next-Generation Tumor Genetic Testing Market Share by Type (2021-2032)
- 8.3 Europe Next-Generation Tumor Genetic Testing Market Size by Application
- 8.3.1 Europe Next-Generation Tumor Genetic Testing Market Size by Application (2021-2026)
- 8.3.2 Europe Next-Generation Tumor Genetic Testing Market Size by Application (2027-2032)
- 8.3.3 Europe Next-Generation Tumor Genetic Testing Market Share by Application (2021-2032)
- 8.4 Europe Next-Generation Tumor Genetic Testing Market Size by Country
- 8.4.1 Europe Next-Generation Tumor Genetic Testing Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 8.4.3 Europe Next-Generation Tumor Genetic Testing Market Size by Country (2027-2032)
- 8.4.4 Europe Next-Generation Tumor Genetic Testing Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Next-Generation Tumor Genetic Testing Market Size (2021-2032)
- 9.2 China Next-Generation Tumor Genetic Testing Market Size by Type
- 9.2.1 China Next-Generation Tumor Genetic Testing Market Size by Type (2021-2026)
- 9.2.2 China Next-Generation Tumor Genetic Testing Market Size by Type (2027-2032)
- 9.2.3 China Next-Generation Tumor Genetic Testing Market Share by Type (2021-2032)
- 9.3 China Next-Generation Tumor Genetic Testing Market Size by Application
- 9.3.1 China Next-Generation Tumor Genetic Testing Market Size by Application (2021-2026)
- 9.3.2 China Next-Generation Tumor Genetic Testing Market Size by Application (2027-2032)
- 9.3.3 China Next-Generation Tumor Genetic Testing Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Next-Generation Tumor Genetic Testing Market Size (2021-2032)
- 10.2 Asia Next-Generation Tumor Genetic Testing Market Size by Type
- 10.2.1 Asia Next-Generation Tumor Genetic Testing Market Size by Type (2021-2026)
- 10.2.2 Asia Next-Generation Tumor Genetic Testing Market Size by Type (2027-2032)
- 10.2.3 Asia Next-Generation Tumor Genetic Testing Market Share by Type (2021-2032)
- 10.3 Asia Next-Generation Tumor Genetic Testing Market Size by Application
- 10.3.1 Asia Next-Generation Tumor Genetic Testing Market Size by Application (2021-2026)
- 10.3.2 Asia Next-Generation Tumor Genetic Testing Market Size by Application (2027-2032)
- 10.3.3 Asia Next-Generation Tumor Genetic Testing Market Share by Application (2021-2032)
- 10.4 Asia Next-Generation Tumor Genetic Testing Market Size by Country
- 10.4.1 Asia Next-Generation Tumor Genetic Testing Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 10.4.3 Asia Next-Generation Tumor Genetic Testing Market Size by Country (2027-2032)
- 10.4.4 Asia Next-Generation Tumor Genetic Testing Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Type
- 11.2.1 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Application
- 11.3.1 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Country
- 11.4.1 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Next-Generation Tumor Genetic Testing Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst